Agilex Biolabs

As the only FDA-inspected bioanalytical laboratory of its type in Australia, Agilex Biolabs occupies a distinctive position in the Asia-Pacific clinical trial services market. Based in Australia, the company serves contract research organisations and sponsors requiring rigorous bioanalytical and toxicology support throughout drug development.

The laboratory's core capability is pharmacokinetics (PK) analysis, covering the full time course of drug absorption, bioavailability, distribution, metabolism, and excretion. Complementing this is pharmacodynamics (PD) work, which addresses the biochemical, physiological, and molecular effects of a therapeutic on the body. Together, these services provide sponsors with an integrated view of drug behaviour in clinical studies.

Agilex Biolabs operates across several analytical disciplines. LC-MS/MS bioanalysis and immunoassays (ligand binding assays) underpin small and large molecule quantification. The team also conducts immunogenicity testing, including anti-drug antibody and neutralising antibody assays, alongside vaccine and cell-based immunology assays and flow cytometry. Biomarker services are an active component of the offering, providing efficacy, safety, and pathology data relevant to the indication under investigation.

For multi-site programmes, the laboratory provides end-to-end central lab services, managing the entire sample lifecycle including kit production and distribution to clinical sites. Off-the-shelf assays are available to reduce time and cost for sponsors with more standard bioanalytical requirements.

The company's FDA-inspected status makes it a credible option for global programmes requiring a compliant Southern Hemisphere facility, particularly where an Australian clinical footprint or regulatory alignment is relevant to the development strategy.

Further information is available at agilexbiolabs.com.